Table: Taisho Pharmaceutical HD -2021/22 parent results
May 13 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2022 Mar 31, 2021 Mar 31, 2023 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 10.03 4.20
(+138.9 pct) (-30.1 pct)
Operating 8.36 2.49
(+235.7 pct) (-39.8 pct)
Recurring 8.26 2.47
(+235.0 pct) (-39.5 pct)
Net 10.69 1.87
(+472.1 pct) (-39.7 pct)
EPS 131.16 yen 23.40 yen
EPS Diluted 131.01 yen 23.37 yen
Ann Div 100.00 yen 100.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 50.00 yen 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10